Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear.

Methods

The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.

Results

A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had <15 lymph nodes examined. Multivariate Cox regression identified higher Charlson score, <15 lymph nodes examined, higher tumor grade, and tumor location in the cardia as factors associated with significantly decreased overall survival. With a median follow-up of 36 months, the 5-year overall survival was 71 % for patients with ≥15 lymph nodes examined and 53 % for those with <15 lymph nodes (p < 0.001). In patients who had <15 lymph nodes examined, there was an overall survival benefit for adjuvant chemoradiation (hazard ratio 0.71, p = 0.043). In patients with ≥15 lymph nodes examined, no survival benefit for adjuvant therapy was identified (p > 0.74).

Conclusions

Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  CAS  PubMed  Google Scholar 

  2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  3. Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol. 2008;15(2):500–7.

    Article  PubMed  Google Scholar 

  4. Seyedin S, Wang PC, Zhang Q, Lee P. Benefit of adjuvant chemotherapy for gastric adenocarcinoma: a SEER analysis. Gastrointest Cancer Res. 2014;7(3–4):82–90.

    PubMed  PubMed Central  Google Scholar 

  5. Jin LX, Moses LE, Squires MH 3rd et al. Factors associated with recurrence and survival in lymph node-negative gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative. Ann Surg. 2015. doi:10.1097/SLA.0000000000001084.

    Google Scholar 

  6. Du C, Zhou Y, Huang K, Zhao G, Fu H, Shi Y. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg. 2011;15(12):2153–8.

    Article  PubMed  Google Scholar 

  7. Brar SS, Mahar AL, Helyer LK, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014;149(1):18–25.

    Article  PubMed  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. 2015. http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf.

  9. Gold JS, Al Natour RH, Saund MS, et al. Population-based outcome of stage IA-IIA resected gastric adenocarcinoma: who should get adjuvant treatment? Ann Surg Oncol. 2013;20(7):2304–10.

    Article  PubMed  Google Scholar 

  10. Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.

    Article  PubMed  Google Scholar 

  11. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.

    Article  PubMed  Google Scholar 

  12. Hartgrink HH, van de Velve CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004; 22:2069.

    Article  CAS  PubMed  Google Scholar 

  13. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–900.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Commission on Cancer. Facility Oncology Registry Data Standards (FORDS). Chicago, IL: American College of Surgeons; 2012.

    Google Scholar 

  15. Deyo, RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.

    Article  CAS  PubMed  Google Scholar 

  16. Fritz, A, Percy, C, Jack, A, Shanmugaratnam, K, Sobin, L, Parkin, DM, Whelan, S, editors. International Classification of Diseases for Oncology. 3rd edn. Geneva: World Health Organization; 2000.

    Google Scholar 

  17. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th edn. Chicago: Springer; 2010.

    Book  Google Scholar 

  18. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.

    Article  CAS  PubMed  Google Scholar 

  19. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol. 2008;34(11):1208–16.

    Article  CAS  PubMed  Google Scholar 

  20. Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415.

    PubMed  Google Scholar 

  21. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.

    Article  CAS  PubMed  Google Scholar 

  23. Dai Q, Jiang L, Lin RJ, Wei KK, Gan LL, Deng CH, Guan QL. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–84.

    Article  PubMed  Google Scholar 

  24. Snyder RA, Castaldo ET, Bailey CE, Phillips SE, Chakravarthy AB, Merchant NB. Survival benefit of adjuvant radiation therapy for gastric cancer following gastrectomy and extended lymphadenectomy. Int J Surg Oncol. 2012; doi:10.1155/2012/307670.

    PubMed  PubMed Central  Google Scholar 

  25. Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol. 2005;12(12):981–7.

    Article  PubMed  Google Scholar 

  26. Bilimoria KY, Talamonti MS, Wayne JD, et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg. 2008;143(7):671–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Surgery, The University of Chicago, Chicago, IL, USA

      Haejin In MD, MBA, MPH, Olga Kantor MD, Susan M. Sharpe MD, Marshall S. Baker MD, MBA, Mark S. Talamonti MD & Mitchell C. Posner MD

    2. Department of Surgery, Montefiore Medical Center, Bronx, NY, USA

      Haejin In MD, MBA, MPH

    3. Department of Surgery, NorthShore University HealthSystems, Evanston, IL, USA

      Marshall S. Baker MD, MBA & Mark S. Talamonti MD

    4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA

      Haejin In MD, MBA, MPH

    Authors
    1. Haejin In MD, MBA, MPH
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Olga Kantor MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Susan M. Sharpe MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Marshall S. Baker MD, MBA
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Mark S. Talamonti MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Mitchell C. Posner MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Haejin In MD, MBA, MPH.

    Additional information

    Haejin In and Olga Kantor have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    In, H., Kantor, O., Sharpe, S.M. et al. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol 23, 1956–1962 (2016). https://doi.org/10.1245/s10434-015-5075-1

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-015-5075-1

    Keywords

    Search

    Navigation